厄瓜多尔新冠病毒检测的不足之处：是时候激励研究与创新了。
The Shortcomings of COVID-19 Testing in Ecuador: Time to Incentivize Research and Innovation.
作者信息
Chalen Izan, Cobo María Mercedes, Gutierrez Bernardo, Carrazco-Montalvo Andrés, Ponce Patricio, Cisneros-Heredia Diego F
机构信息
Colegio de Ciencias Biológicas y Ambientales COCIBA, Universidad San Francisco de Quito USFQ, Quito 170901, Ecuador.
Beckman Institute, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA.
出版信息
Life (Basel). 2022 Feb 22;12(3):325. doi: 10.3390/life12030325.
The COVID-19 pandemic hit Ecuador severely. The country caught the attention of international media due to its high death toll and overwhelmed healthcare system. The clinical diagnostics system was rapidly overloaded, and the import of PCR tests was delayed. The case of Ecuador illustrates how middle-income countries rely heavily on the importation of biotechnological products for their healthcare systems. The Ecuadorian experience during the COVID-19 pandemic serves as a call for the formation of policies for the development of the biotechnological industry.
新冠疫情对厄瓜多尔造成了严重打击。该国因其高死亡率和不堪重负的医疗系统而引起了国际媒体的关注。临床诊断系统迅速不堪重负，聚合酶链反应（PCR）检测试剂的进口也出现延误。厄瓜多尔的情况表明，中等收入国家的医疗系统在很大程度上依赖生物技术产品的进口。厄瓜多尔在新冠疫情期间的经历呼吁制定生物技术产业发展政策。
Zotero 插件